Idiopathic Pulmonary Fibrosis

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
NCT05130970 | PHASE 2 | INTERVENTIONAL

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).

Trial Information
47 Sites
81 Participants
Recruiting
40 Years to 8 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
The University of Alabama at Birmingham
Birmingham,Alabama,United States,35205
Pulmonary Associates Clinical Trials AZ
Phoenix,Arizona,United States,85032
National Institute of Clinical Research
Huntington Beach,California,United States,92647
University of Southern California Center for Advanced Lung Disease
Los Angeles,California,United States,90033
University of California Irvine
Orange,California,United States,92868
Meris Clinical Research
Brandon,Florida,United States,33511
Lakes Research
Miami Lakes,Florida,United States,33014
Reliant Medical Research
Miami,Florida,United States,33165
US Associates in Research LLC
Miami,Florida,United States,33175
Renstar Medical Research
Ocala,Florida,United States,34471
Central Florida Pulmonary Group, PA
Orlando,Florida,United States,32803
University of Kansas Medical Center
Kansas City,Kansas,United States,66160
Jadestone Clinical Research
Silver Spring,Maryland,United States,20904
Hannibal Clinic
Hannibal,Missouri,United States,63401
Weill Cornell Medical Center
New York,New York,United States,10021
Superior Clinical Research
Smithfield,North Carolina,United States,27577
Southeastern Research Center
Winston-Salem,North Carolina,United States,27103
University of Cincinnati
Cincinnati,Ohio,United States,45267
University of Oklahoma Health Sciences Center
Oklahoma City,Oklahoma,United States,73104
Temple University TMS
Philadelphia,Pennsylvania,United States,19140
Clinical Trial Center of Middle Tennesse
Franklin,Tennessee,United States,37067
Elite Medical Research
Dallas,Texas,United States,75230
Southwest Family Medicine Associates
Dallas,Texas,United States,75235
Baylor Scott and White Health Advanced Lung Disease Specialists
Dallas,Texas,United States,75246
Baylor College of Medicine
Houston,Texas,United States,77030
Royal Adelaide Hospital
Adelaide,Australia,5000
Medizinische Univeritt Graz
Graz,Austria,8036
Kepler Universittsklinikum
Linz,Austria,4021
Universitair Ziekenhuis (UZ) Leuven
Leuven,Belgium,3000
Centre Hospitalier Universitaire Sart Tilman
Liège,Belgium,4000
St. Joseph's Healthcare Hamilton
Hamilton,Ontario,Canada,L8N4A6
Dr. Syed Anees Medicine Professional Corporation
Windsor,Ontario,Canada,N8X1T3
Odense Universitetshospital Lungemedicinsk Forskningsenhed
Odense,Denmark,5000
Fachkrankenhaus Coswig GmbH
Coswig,Germany,01640
Universitaetsklinikum Essen Ruhrlandklinik (Westdeutsches Lungenzentrum)
Essen,Germany,45239
Medizinische Hochschule Hannover Klinik fr Pneumologie
Hannover,Germany,30625
Petrus Krankenhaus Wuppertal
Wuppertal,Germany,42283
Azienda Ospedaliera Universitaria Ospedali Riuniti Foggia
Foggia,Italy,71122
Centrum Medycyny Oddechowej Bialymstoku
Białystok,Poland,15-044
Twoja Przychodnia Centrum Medyczne Nowa Sol
Nowa Sol,Poland,67-100
Centrum Bada Klinicznych NZOZ
Wrocław,Poland,51-162
Giromed Institute, SLP
Barcelona,Spain,08006
Hospital Universitario Puerta del Mar (HUPM)
Cadiz,Spain,11009
The Churchill Hospital Oxford University Hospitals NHS Trust
Oxford,MD,United Kingdom,OX37LE
Queen Elizabeth Hospital
Birmingham,United Kingdom,B152GW
Altnagelvin Area Hospital
Londonderry,United Kingdom,BT476SB
Manchester Univ NHS Wythenshawe Hospital
Manchester,United Kingdom,M239LT

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov